ANTIPLATELET ACTIVITY OF ORIGINAL CLOPIDOGREL AND ITS GENERIC: RESULTS OF RANDOMIZED COMPARATIVE CROSS-OVER STUDY

<p><strong>Objective</strong> — to study therapeutic equivalence (efficacy, safety and tolerability) and hemorheological activity of original clopidogrel and its<br />generic in patients of high cardiovascular risk.</p><p><br /><strong>Materials and me...

Full description

Bibliographic Details
Main Authors: V. V. Yakusevich, A. S. Petrochenko, V. S. Simonov, N. Yu. Levshin, A. D. Deev
Format: Article
Language:Russian
Published: ABV-press 2014-07-01
Series:Klinicist
Subjects:
Online Access:http://klinitsist.abvpress.ru/index.php/Klin/article/view/87
_version_ 1797971446502260736
author V. V. Yakusevich
A. S. Petrochenko
V. S. Simonov
N. Yu. Levshin
A. D. Deev
author_facet V. V. Yakusevich
A. S. Petrochenko
V. S. Simonov
N. Yu. Levshin
A. D. Deev
author_sort V. V. Yakusevich
collection DOAJ
description <p><strong>Objective</strong> — to study therapeutic equivalence (efficacy, safety and tolerability) and hemorheological activity of original clopidogrel and its<br />generic in patients of high cardiovascular risk.</p><p><br /><strong>Materials and methods</strong>. 50 patients with stable angina pectoris were randomized into 2 groups of consecutive 2-week treatment by original<br />(plavix) and generic (plagril) clopidogrel and vice versa. ADP-induced platelet aggregation was measured at baseline and after treatment by<br />each of the drugs. Physical examination and adverse events were evaluated at visits.</p><p><br /><strong>Results</strong>. After the first treatment period a significant decrease of platelet aggregation was determined in both groups. After switching to another<br />drug the decrease continued but not significantly in both groups. There were registered no adverse events associated with antiplatelet therapy.</p><p><br /><strong>Conclusion.</strong> Equal antiplatelet activity established for plavix and plagril demonstrates their therapeutic equivalence.</p>
first_indexed 2024-04-11T03:32:48Z
format Article
id doaj.art-d6611b485d0a45e3a8d911fda156f39b
institution Directory Open Access Journal
issn 1818-8338
language Russian
last_indexed 2024-04-11T03:32:48Z
publishDate 2014-07-01
publisher ABV-press
record_format Article
series Klinicist
spelling doaj.art-d6611b485d0a45e3a8d911fda156f39b2023-01-02T06:12:03ZrusABV-pressKlinicist1818-83382014-07-01546470102ANTIPLATELET ACTIVITY OF ORIGINAL CLOPIDOGREL AND ITS GENERIC: RESULTS OF RANDOMIZED COMPARATIVE CROSS-OVER STUDYV. V. Yakusevich0A. S. Petrochenko1V. S. Simonov2N. Yu. Levshin3A. D. Deev4Yaroslavl State Medical Academy, Ministry of Health and Social Development of RussiaYaroslavl State Medical Academy, Ministry of Health and Social Development of RussiaYaroslavl State Medical Academy, Ministry of Health and Social Development of RussiaYaroslavl State Medical Academy, Ministry of Health and Social Development of RussiaState Research Center for Preventive Medicine, Ministry of Health and Social Development of Russia<p><strong>Objective</strong> — to study therapeutic equivalence (efficacy, safety and tolerability) and hemorheological activity of original clopidogrel and its<br />generic in patients of high cardiovascular risk.</p><p><br /><strong>Materials and methods</strong>. 50 patients with stable angina pectoris were randomized into 2 groups of consecutive 2-week treatment by original<br />(plavix) and generic (plagril) clopidogrel and vice versa. ADP-induced platelet aggregation was measured at baseline and after treatment by<br />each of the drugs. Physical examination and adverse events were evaluated at visits.</p><p><br /><strong>Results</strong>. After the first treatment period a significant decrease of platelet aggregation was determined in both groups. After switching to another<br />drug the decrease continued but not significantly in both groups. There were registered no adverse events associated with antiplatelet therapy.</p><p><br /><strong>Conclusion.</strong> Equal antiplatelet activity established for plavix and plagril demonstrates their therapeutic equivalence.</p>http://klinitsist.abvpress.ru/index.php/Klin/article/view/87clopidogrelequivalenceplavixplagril
spellingShingle V. V. Yakusevich
A. S. Petrochenko
V. S. Simonov
N. Yu. Levshin
A. D. Deev
ANTIPLATELET ACTIVITY OF ORIGINAL CLOPIDOGREL AND ITS GENERIC: RESULTS OF RANDOMIZED COMPARATIVE CROSS-OVER STUDY
Klinicist
clopidogrel
equivalence
plavix
plagril
title ANTIPLATELET ACTIVITY OF ORIGINAL CLOPIDOGREL AND ITS GENERIC: RESULTS OF RANDOMIZED COMPARATIVE CROSS-OVER STUDY
title_full ANTIPLATELET ACTIVITY OF ORIGINAL CLOPIDOGREL AND ITS GENERIC: RESULTS OF RANDOMIZED COMPARATIVE CROSS-OVER STUDY
title_fullStr ANTIPLATELET ACTIVITY OF ORIGINAL CLOPIDOGREL AND ITS GENERIC: RESULTS OF RANDOMIZED COMPARATIVE CROSS-OVER STUDY
title_full_unstemmed ANTIPLATELET ACTIVITY OF ORIGINAL CLOPIDOGREL AND ITS GENERIC: RESULTS OF RANDOMIZED COMPARATIVE CROSS-OVER STUDY
title_short ANTIPLATELET ACTIVITY OF ORIGINAL CLOPIDOGREL AND ITS GENERIC: RESULTS OF RANDOMIZED COMPARATIVE CROSS-OVER STUDY
title_sort antiplatelet activity of original clopidogrel and its generic results of randomized comparative cross over study
topic clopidogrel
equivalence
plavix
plagril
url http://klinitsist.abvpress.ru/index.php/Klin/article/view/87
work_keys_str_mv AT vvyakusevich antiplateletactivityoforiginalclopidogrelanditsgenericresultsofrandomizedcomparativecrossoverstudy
AT aspetrochenko antiplateletactivityoforiginalclopidogrelanditsgenericresultsofrandomizedcomparativecrossoverstudy
AT vssimonov antiplateletactivityoforiginalclopidogrelanditsgenericresultsofrandomizedcomparativecrossoverstudy
AT nyulevshin antiplateletactivityoforiginalclopidogrelanditsgenericresultsofrandomizedcomparativecrossoverstudy
AT addeev antiplateletactivityoforiginalclopidogrelanditsgenericresultsofrandomizedcomparativecrossoverstudy